Sugi Predict

Sugi Predict / Compounds / SCHEMBL20529670

SCHEMBL20529670

SCHEMBL20529670

O=[N+]([O-])c1ccc(Br)cc1NCC(F)F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ MAPK1 P28482 3/20 0.40
▸ PKM P14618 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KAT2B Q92831 1/20 0.39
▸ HTR6 P50406 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ GLA P06280 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ S100A4 P26447 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30371569 1.00 MAPT (0.44) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL30425152 0.88 MAPK1 (0.48) MAPTALDH1A1MAPK1PKMRAB9A
SCHEMBL17042584 0.88 MAPK1 (0.48) MAPTALDH1A1MAPK1PKMRAB9A
SCHEMBL991433 0.85 MAPT (0.60) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18496385 0.83 MAPT (0.46) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL29719344 0.83 MAPT (0.46) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18496256 0.80 MAPT (0.46) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18496253 0.80 MAPT (0.46) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18496355 0.80 MAPT (0.46) MAPTALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL18496246 0.80 MAPT (0.46) MAPTALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415816-B1 PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A BIOSPLICE THERAPEUTICS INC (US) 2026-03-18 — — EP disclosed
EP-4676931-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BioSplice Therapeutics, Inc. (US) 2026-01-14 — — EP disclosed
US-12492188-B2 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis BRISTOL-MYERS SQUIBB COMPANY (US) 2025-12-09 — — US disclosed
WO-2025137469-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250206746-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-06-26 — — US disclosed
US-20250171466-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-05-29 — — US disclosed
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US disclosed
EP-4200292-B1 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2024-11-13 — — EP disclosed
US-12134625-B2 Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof BIOSPLICE THERAPEUTICS, INC. (US) 2024-11-05 — — US disclosed
WO-2024211797-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
CN-116075510-A 1H-benzo [ d ] imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis 百时美施贵宝公司 2023-05-05 — — CN disclosed
WO-2023064366-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed
WO-2022040260-A1 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-02-24 — — WO disclosed
WO-2022040260-A1 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-02-24 — — WO disclosed
US-20210355118-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-11-18 — — US disclosed
WO-2020128036-A1 MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-06-25 — — WO disclosed
WO-2020128036-A1 MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-06-25 — — WO disclosed
WO-2018187480-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355118-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B MAPT 670/4885ALDH1A1 916/4885CYP1A2 1988/4885
US-12492188-B2 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis TLR9, TLR1, TLR7 MAPT 4616/4885ALDH1A1 1720/4885CYP1A2 4680/4885
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 MAPT 341/4885ALDH1A1 3447/4885CYP1A2 3655/4885
US-20250206746-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B MAPT 402/4885ALDH1A1 1941/4885CYP1A2 3121/4885
US-20250171466-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B MAPT 330/4885ALDH1A1 3236/4885CYP1A2 3748/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 MAPT 341/4885ALDH1A1 3447/4885CYP1A2 3655/4885
US-12134625-B2 Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof DYRK1A, DYRK2, DYRK1B MAPT 330/4885ALDH1A1 3236/4885CYP1A2 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.